Investigating the effects of dexamethasone on pulmonary surfactant lipids based on lipidomics studies.
Biomed Chromatogr
; 38(9): e5937, 2024 Sep.
Article
en En
| MEDLINE
| ID: mdl-38922717
ABSTRACT
Dexamethasone, a glucocorticoid commonly used in pediatric patients, has potent anti-inflammatory and immunosuppressive properties. However, it is associated with side effects such as reduced lung function and decreased immunity. Pulmonary surfactant lipids are closely linked to lung disease and play a role in reducing surface tension, immune response and antiviral activity. The dysregulation of lipid metabolism is closely associated with lung disease. Hence, untargeted lipidomics may be instrumental in elucidating the effects of dexamethasone on pulmonary surfactant lipids. We obtained surfactant lipid samples from the bronchoalveolar lavage fluid of young mice injected subcutaneously with dexamethasone and conducted a comprehensive lipidomic analysis, comparing them with a control group. We observed a decrease in lipids, such as phosphatidylcholine, phosphatidylglycerol and phosphatidylethanolamine, and an increase in ceramide, fatty acid, diacylglycerol and monoglyceride, which may impact lung health. This study revealed the influence of dexamethasone on pulmonary surfactant lipids, offering new insights into adverse reactions in clinical settings.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Surfactantes Pulmonares
/
Dexametasona
/
Líquido del Lavado Bronquioalveolar
/
Lipidómica
/
Lípidos
Límite:
Animals
Idioma:
En
Revista:
Biomed Chromatogr
Año:
2024
Tipo del documento:
Article
País de afiliación:
China